CURRICULUM  VITA

JAN  LEWIS  BRANDES

EDUCATION:              

• M.D., Vanderbilt University School of Medicine, Nashville, Tennessee, Awarded May 1989.

• Fulbright Scholar, Robert Koch Institute of Virology, Free University, West Berlin, Federal Republic of Germany 1982-83.

• M.S., University of Tennessee, Knoxville, Tennessee.  1980.  Awarded in Microbiology.

• Honors:  George Cameron Award.  Thesis title:  Detection of Virus-Specific Glycoproteins Within Herpes Simples Virus Transformed Cells.

• B.S., Mississippi University of Women, Columbus, Mississippi.  1975.  Awarded cum laude in Biology.  Honors:  Dean’s List, Hall of Fame, Mortar Board, and Who’s Who in American Colleges and Universities.

POST  GRADUATE  MEDICAL  TRAINING:

• Chief Resident in Neurology.  July 1992 – June 1993.  Vanderbilt University Medical Center, Nashville, Tennessee.

• Resident in Neurology.  1990-92.  Vanderbilt University Medical Center, Nashville, Tennessee.

• Intern in Internal Medicine.  1989-90.  Vanderbilt University Medical Center, Nashville, Tennessee.

CLINICAL  PRACTICE  /  APPOINTMENTS:

• Neurologist, Nashville Neuroscience Group, Nashville, Tennessee.  July 1, 1996 to present.

• Neurologist, The Neurology Group, a division of The Otology Group, Nashville, Tennessee.  November 1995 to July 1, 1996,  currently consulting neurologist.

• Clinical Instructor, Department of Neurology, Vanderbilt University School of Medicine, Nashville, Tennessee, July 1993 to present.

• Neurologist (private practice), Neurologic Consultants, P.C., Nashville, Tennessee. September 1993 to October 1995.

MEDICAL  LICENSURE:

• Licensure, Tennessee Board of Medical Examiners, December 3, 1991 (#MD-022045).

• Certification, National Board of Medical Examiners, March 7, 1990 (#358278).

• Certification, American Board of Psychiatry and Neurology, April 1996 (#42783)

MEDICAL  COMMITTEES  AND  HONORS:

• Fellow, American Headache Society

• Book Editor, Headache, June 2001 to present.

• Member, Editorial Board of Headache, June 2001 to present.

• Member, Alpha Omega Alpha, Medical Honor Society, elected 1991.

• Member, American Medical Association.

• Member, Tennessee Medical Association.

• Member, Nashville Academy of Medicine.

• Member (active), American Academy of Neurology.

• Member, American Headache Society, currently on Ethics Committee.

• Member, Review Board, American Association for the Study of Headache, 1998.

• Consultant, Organizing Committee, 10th Congress of the International Headache Society, New York, New York, June 29 – July 3, 2001.

• Member, Board of Directors, American Council for Headache Education (ACHE), 2001-present.

• Medical Steering Committee, MAZE Patient Survey, September 2000.

• Medical Advisory Board, The EAR Foundation, Nashville, Tennessee

• Member, Board of Directors, Vanderbilt Medical Alumni

• Member, Academic Programs Committee, Vanderbilt University Medical School 1996-97.

• Named to Best Doctors in the Midwest, 1996-97, 1998-99

CLINICAL  TRIALS:

Principal Investigator, Clopidogrel, Prevention of Ischemic Complications, EFC4505,

Sanofi Synthelabo Recherche, 2002.

Principal Investigator, Zolmitriptan Nasal Spray, Acute Treatment of Migraine,    

311CUS/0022, AstraZeneca, 2002.

Principal Investigator, Imitrex Nasal Spray, Adolescent Acute Treatment of Migraine,

SUM30045, GlaxoSmithKline, 2002.

Principal Investigator, Sumatriptan, Migrainous Disorder, GlaxoSmithKline, 2002

Principal Investigator, Novartis,  Trileptal, Prophylactic Therapy, Migraine Headaches,     

2002.

Principal Investigator, Allergan, Prophylactic Treatment of Migraine Headache, 191622-

037-01, 2002 – 2003.

Principal Investigator, Allergan, Prophylactic Treatment of Chronic Headache    Population, 191622-038-02, 2002-2003.

Principal Investigator, Pfizer, Early Treatment of Migraine, Eletriptan, A1601080, 2002.

Principal Investigator, Zolmitriptan ZMT, Acute Treatment of Migraine, 311CUS/0016,

AstraZeneca, 2002.  

Principal Investigator, Sumatriptan, Acute Treatment of Migraine, SUM40298,

GlaxoSmithKline, 2002.

Principal Investigator, Lamotrigine or Valproate, PCOS in female subjects with newly

diagnosed epilepsy, LAM30007, GlaxoSmithKline, 2002.

Principal Investigator, Clopidogrel, Management of Atherothrombosis, Sanofi-

Synthelabo, MATCH, 2002.

Principal Investigator, Civamide, Acute Treatment of Cluster Headache, Winston

Laboratories, Inc., WL-1001-02-02, 2002.

Principal Investigator, Sumatriptan, Acute Treatment of Menstrually Associated Migraine

During the Mild Phase, GlaxoSmithKline, SUM40285, 2001-2002.

Principal Investigator, Myobloc, Meuromuscular Data (MIND) Registry, Elan

Pharmaceuticals, 2001-2002.

Principal Investigator, Rofecoxib, Acute Treatment of Migraine, 161-00, Merck, 2001.

Principal Investigator, Sumatriptan, Acute Treatment of Migraine, Adolescent Trial,

SUM40276,  Glaxo-Wellcome, 2000-2001.

Principal Investigator, Rizatriptan, Acute Treatment of Migraine in Adolescents,

MK0462 – 061, Merck, 2001.

Principal Investigator, Sumatriptan, Mild Pain Phase of Menstrually-Associated Migraine

Attack, GlaxoSmithKline, 2001.

Principal Investigator, Levetiracetam, Prophylactic Treatment of Migraine, N01014,

UCB Pharma, Inc., 2001.

Principal Investigator, Topiramate, Prophylaxis of Migraine, TOPMAT-MIGR-002,

R.W. Johnson, 2001.

Principal Investigator, Zolmitriptan, Acute Treatment of Migraine, 311CUS/0015,

AstraZeneca, 2001.

Principal Investigator, Sumatriptan, Early Intervention of Migraine Pain,

            SUM40274/SUM40275/SUM40276, Glaxo Wellcome, 2000.

Principal Investigator, Montelukast and Rofecoxib, Prophylaxis of Migraine Attacks,

125-00, Merck & Co., Inc., April 2000.

Principal Investigator, Topiramate, Treatment of Diabetic Neuropathy Pain,

PRI/TOP/INT/24, R. W. Johnson, 2000.

Principal Investigator, Headache Assessment Study in Primary Care, SX080A99, Pfizer,

            April 2000.

Principal Investigator, Menstrual Migraine Study, S2W40027, Glaxo Wellcome, April

2000.

Principal Investigator, Amerge, Menstrual Migraine Study, S2W40012, Glaxo Wellcome,         December 1999-2000.

Principal Investigator, Oral GV196771, Prophylaxis in Migraine Headache Attacks,

Glaxo-Wellcome, 1999.

Principal Investigator, Botox, Prophylactic Treatment of Migraine, 191622-024-00-

1916222-026-00, Allergan, May 1999-2000.

Principal Investigator, Rizatriptan, Menstrual Migraine Study, MAX478, Merck & Co.,

Inc., October 1999 – May 2000.

Principal Investigator, Naratriptan, Menstrual Migraine Study, S2WA4006, Glaxo

Wellcome, 1998.

Principal Investigator, Bristol-Myers Squibb, Dose Response Trial of BMS-204352 in

Acute   Stroke, June 1998-99.

Co-Investigator, International, Multi-Center, Randomized Group Study of GV 150526 in

the Treatment of Patients with a Clinical Diagnosis of Acute Stroke, Glaxo

Wellcome, 1998.

Principal Investigator, Naratriptan, Adolescent Migraine Study, S2WA-3012, Glaxo

Wellcome, 1995-1996

Co-Investigator, ANCROD Stroke Trial, Collaborative Study through Vanderbilt

University Medical Center and Saint Thomas Hospital, 1993-1994.

Co-Investigator, Tissue Plasminogen Activator Trial, Vanderbilt University Medical

Center, 1992-1993.

HOSPITAL  AFFILIATIONS:

• Baptist Hospital, Nashville, Tennessee.

• Centennial Medical Center, Nashville, Tennessee.

• Saint Thomas Hospital, Nashville, Tennessee.

• Vanderbilt University Medical Center, Nashville, Tennessee.

• Stallworth Rehabilitation Hospital, Vanderbilt University Medical Center, Nashville, Tennessee.

• Veteran’s Administration Medical Center, Nashville, Tennessee.

PREVIOUS  WORK  EXPERIENCE:

• Assistant Director, Tennessee Water Resources Research Center, University of Tennessee, Knoxville, Tennessee.  1980-82.

• Graduate Research Assistant, Department of Microbiology, University of Tennessee, Knoxville,Tennessee.  1978-80.

• Graduate Teaching Assistant, Department of Microbiology, University of Tennessee, Knoxville, Tennessee.  1977-78.

• Director of Public Relations, North Mississippi Medical Center, Tupelo, Mississippi.  1975-77.

LECTURES:

• National Speaker’s Bureau, Glaxo-Wellcome.

• National Speaker’s Bureau, AstraZeneca Pharmaceutical

• National Speaker’s Bureau, Merck & Co., Inc.

• National Speaker’s Bureau, Allergan

• National Speaker’s Bureau, Pfizer

• National Speaker’s Bureau, Pharmacia

• National Speaker’s Bureau, Ortho-McNeil

• Faculty, Neurology Ambassador Program. 

• National Consultant, Migraine Awareness Program, sponsored by Glaxo-Wellcome. 1997-98.

“Migraine Headaches: Assessment, Management, and Today’s Hot Topics”, The University of North Carolina, Chapel Hill School of Nursing, October 24, 2002.

“Women’s Issues and Migraine”, Neurology Grand Rounds, University of Alabama, Birmingham School of Medicine, November 6, 2002.

“Efficient Headache Diagnosis and Treatment in Primary Care”, Neuroscience for the Primary Care Provider: A Practical Approach, Virginia Commonwealth University, Medical College of Virginia Campus, AstraZeneca, Richmond, VA, September 28, 2002.

14^th Migraine Trust International Symposium, US Migraine Prevention Advisory Board Meeting, Ortho-McNeil Pharmaceutical, Inc., London, England, September 22, 2002.

“Evaluation and Treatment of Headache in the Emergency/Urgent Care Setting”, Department of Emergency Medicine Grand Rounds, Vanderbilt University School of Medicine, GSK, September 16, 2002.

“Caring for Chronically Ill Migraine Patients”, Zomig Regional Advisory Board Meeting, AstraZeneca, Baltimore, MD, August 9-11, 2002.

“Evaluating the Patient with Headache in the Primary Care Setting”, AstraZeneca Nurse Practitioner Faculty Update Meeting, Nashville, TN, July 27, 2002.

“Approaches to Migraine: An Overview of Treatment Strategies Aimed at Maximizing Therapeutic Responses”, Zomig Regional Advisory Board, AstraZeneca, Myrtle Beach, S.C., July 20, 2002 and Adairsville, GA, August 23, 2002.

“Is Menstrual Migraine More Difficult to Manage” Debating the Evidence? CME Symposium, 44^th Annual American Headache Society Meeting, Postgraduate Institute for Medicine, Seattle, WA, June 21, 2002.

Moderator “New Advances and Understandings in the Diagnosis and Care of Migraine Patients”, Primary Care Network, American Headache Society’s 44^th Annual Scientific Meeting, GSK, Seattle, WA, June 21, 2002.

“From Publications to Patients: Utilizing Clinical Data to Individualize Migraine Therapy”, Faculty Member, Symposium 44^th AHS annual meeting, Postgraduate Institute for Medicine, Seattle, WA, June 22, 2002.

“Approaches To Migraine” AstraZeneca Regional Advisory Board Meeting, La Jolla,

California, June 1, 2002.

“Women’s Issues In Headache”, 51^st Kentucky Academy of Family Physicians, Louisville, KY May 17, 2002.

Program Director, Case Studies in Headache, Kick Off Program. American Academy of Neurology, Denver, Colorado, April 13, 2002.

“Approaches to Migraine: An Overview of Treatment Strategies Aimed at Maximizing Therapeutic Response”, Astra-Zeneca Regional Advisory Board Meeting, Bonita Springs, FL, April 6, 2002 & April 27, 2002.

“Management of Difficult Headache Patients – Case Studies”, Merck & Co., Chicago, IL, March 28, 2002.

“Headache in Women, Top 10 Questions”, Mayo Clinic Headache Symposium, Sedona, Arizona, March 16, 2002.

“Management of Migraine in the Reproductive Years”, The University of Kansas Medical Center, Kansas City, KS, March 2, 2002.

“Headache/Migraine in the Perimenopausal and Postmenopausal Woman”, Public Forum, University of Kansas Medical Center, Kansas City, KS, March 2, 2002.

Faculty Moderator, Allergan Headache Clinical Exchange Program, Oklahoma City, OK, February, 26, 2002.

“Women’s Issues and Headache”, Special Population Considerations Symposium, American Headache Society, Headache Now/Bal Harbour 2002, Bal Harbour, Florida, January 19, 2002.

Moderator for American Headache Society Debate: “Analgesic Overuse: Cause or Consequence of Chronic Daily Headache”, Headache Now/Bal Harbour 2002, Bal Harbour, Florida, January 19, 2002.

“Women’s Issues In Migraine”,  Grand Rounds Gundersen Lutheran Medical Center and keynote speaker LaCrosse Area Women’s Health Initiative, Viterbo University,  LaCrosse, Wisconsin, November 2, 2001.

“Hormonal Aspects of Migraine, Part 1”, 1^st North American-Spanish Headache Symposium, Cadiz, Spain, October, 2001.

“Menstrual Migraines”, Annual Meeting of The South Carolina Neurological Association, Mount Pleasant, South Carolina, October 27, 2001.

“MAZE Survey for Patient and General Public Research”, ZOMIG Regional Speaker Update meeting.  San Diego, CA, June 16, 2001 and Hilton Head Island, July 13-15 and 20-22, 2001.

“Perimenopausal Issues in Headache”.  Diamond Headache Update — 2001.  Lake Buena Vista, FL, July 19, 2001.

“Global trends in Migraine Care: Results from the MAZE Survey”. The 10^th Congress of the International Headache Society CME Satellite Symposium, New York, NY, June 30, 2001.

“Headache Diagnosis and Testing”. Neurology Ambassador Program, The 10^th Congress of the International Headache Society IHC 2001, New York, NY, June 29, 2001.

“Prophylaxis in Migraine” in Headache Therapy, Course Director, KMA Welch. 53^rd Annual Meeting of the American Academy of Neurology, Philadelphia, Pennsylvania, May 10,2001.

Moderator, Scientific Session, 53^rd Annual Meeting of the American Academy of Neurology, Philadelphia, Pennsylvania, May 10, 2001.

“Hormonal Aspects of Migraine” and “Post Traumatic Headache”, Annual Headache Symposium, University of South Florida, Tampa, FL, April 27-28, 2001.

Keystone Colorado National Sales Meeting Launch, AstraZeneca, Denver, CO, April 9, 2001.

“Women’s Issues In Migraine”.  Wisconsin Women’s Health Regional Advisory Board.  Wisconsin Dells, WI, March 31, 2001.

“MAZE:  Survey for Patient and General Public Research”.  AstraZeneca Joint Advisory Board Meeting.  Scottsdale, Arizona, October 30-31, 2000.

“Understanding Migraines”.  Living Well:  A New Perspective for Women’s Healthcare in the 00’s.  Denver, Colorado, June 3, 2000.

“Management of Headache”.  Continuing Medical Education Activity, Palmetto Baptist Medical Center, Columbia, South Carolina, October 2000.

 “Management of the Difficult Headache Patient”.  Internal Medicine Grand Rounds, University of Tennessee Medical Center, Knoxville, Tennessee, May 18, 1999.

“Evaluating the Efficacy of Migraine Therapy”.  Migraine National Consultants Meeting, Merck & Co., Miami, Florida, May 15, 1999.

“New Treatments of Migraine”.  16th Annual Family Medicine Primary Care Update, Vanderbilt University Medical Center, Nashville, Tennessee, May 12, 1999.

“Benchmarks for Patient Satisfaction in Clinical Trials”.  Migraine National Consultants Meeting, Merck & Co., Scottsdale, Arizona, March 20, 1999.

“Migraine Diagnosis and Treatment Options”.  Neurology Grand Rounds, Medical University of South Carolina, Charleston, South Carolina, January 1999.

 “New Acute Therapies in Migraine Management”.  Neurology Grand Rounds, Wake Forest University Medical School, North Carolina, December 1998.

“Migraines”.  1998 Annual Assembly and Scientific Program of the Tennessee Academy of Family Physicians, Gatlinburg Convention Center, Gatlinburg, Tennessee, October 1998.

“Cost Effective Management of Headache”.  1998 Vanderbilt University Medical School Reunion, Nashville, Tennessee, October 1998.

“The Difficult Headache Patient”.  1998 Alabama Academy of Neurology Annual National Meeting, Destin, Florida, October 1998.

“The Impact of Migraine”.  1998 Educational Conference of the Academy of Managed Care Pharmacy Symposium, Chicago, Illinois, October 1998.

“Clinical Impact of Migraines”.    Glaxo Wellcome Seminar “Effective Migraine Therapy:  Maximizing Patient Outcomes”, held in conjunction with the 1998 American

Association of Health Plans Institute, Boston, Massachusetts.  June 1998.

“Headache, When to Worry, When to Treat, When to Relax”.  100th Annual Convention and Scientific Seminar of the Tennessee Osteopathic Medical Association,  Opryland Hotel, Nashville, Tennessee.  May 2, 1998.

“Take Charge – Migraine Awareness”.  Rockefeller University, New York, New York, February 1998.

“Interactive Headache Management:  Case Studies”.  “Third Annual Primary Care Medicine for the Ob/Gyn in a Managed Care Arena”, Embassy Suites Resort, Scottsdale,

Arizona, January 24-25, 1997.

“Headache:  A Family Practice Perspective on Diagnosis and Treatment”.  Tennessee Academy of Family Physicians 1995 Annual Scientific Assembly, Gatlinburg Convention Center, Gatlinburg, Tennessee.  October 27, 1995.

“Evaluation and Management of Benign Headache Disorders”.  12th Annual Family Medicine Primary Care Update, Vanderbilt University Medical Center, Nashville, Tennessee, May 20, 1995.

“Neurology of Sleep Disorders”.  Twenty-Fifth Reunion, Department of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee.  September 17, 1994.

“Evaluation and Modern Management of Headaches”.  Evaluation and Management of Neurological Problems for the Primary Care Physician, The University of Tennessee College of Medicine.  Baptist Hospital, Nashville, Tennessee.  December 10, 1994.

“Common Headache Syndrome:  Diagnosis and Treatment”.  Primary Care Update, 1994.  Saint Thomas Hospital, Nashville, Tennessee.  November 2, 1994.

“The Neurological Examination”.  Annual Lecture to First Year Medical School Class, Vanderbilt University School of Medicine, Nashville, Tennessee.  1993 to present.

Regular lectures at The Institute at Baptist Hospital, Grand Rounds at Centennial Medical Center, Baptist Hospital, Vanderbilt University Medical Center, and regional hospitals.

NON-MEDICAL  ACTIVITIES:

Sustainer, Junior League of Nashville, 1988 – present.

Member, Board of Directors, Nashville Opera, 1994 – present.

Member, West End United Methodist Church, Nashville, Tennessee.

Docent, Cheekwood Botanical Gardens and Fine Arts Center, Nashville, Tennessee, 1985-88.

LANGUAGE AND FOREIGN EXPERIENCE:

German.  Resided in West Berlin, Federal Republic of Germany, 1982-83.  (on Fulbright Scholarship).

PUBLICATIONS  AND/OR  PAPERS  PRESENTED:

“Global Trends in Migraine Care – Results from the MAZE Survey”, JL Brandes, CNS Drugs 2002; 16 Suppl. 1: 13-18.

“Impact of Co-morbid Depression on Migraine Disability in Clinical Practice: Preliminary Observations”, Jan L. Brandes, Poster accepted at the American Society of Headache Meeting, Seattle, WA, June 21 – 23, 2002.

“Quetiapine for Migraine Prophylaxis”, Brandes, Jan Lewis, Roberson, Susan C.,

Pearlman, Starr H., and Abu-Shakra, Susan. Poster Accepted at the American Society of Headache Meeting, Seattle, WA, June 21 – 23, 2002.

“Quetiapine for Migraine Prophylaxis”. Brandes, Jan Lewis, Roberson, Susan C., Pearlman, Starr H., and Abu-Shakra, Susan. Poster presented at the 54^th Annual Meeting of the American Academy of Neurology, Denver, CO., April 11 – 19, 2002.

“Impact of Co-morbid Depression on Migraine Disability in Clinical Practice: Preliminary Observations”, Jan L. Brandes, Platform presented at the 54^th Annual Meeting of the American Academy of Neurology, Denver, CO., April 11 – 19, 2002.

Migraine Pain and Women, Monograph, SynerMed Communications, December, 2001, Vol.19, No. 5.

“Neuromodulation of Late Life Migrainous Accompaniments with Topiramate Therapy”. 10th Congress of the International Headache Society IHC 2001, New York, NY, June 29, 2001.

“Potential of the Migraine Disability Assessment (MIDAS) Questionnaire as a public health initiative and in clinical practice”. J. Edmeads, J.M. Lainez, J.L. Brandes, J. Schoenen, and F. Freitag. Neurology, Volume 56, Supplement 1, March 2001.

“Migraine prevalence and treatment patterns: results of the global Migraine and Zolmitriptan Evaluation (MAZE) survey”.  EA MacGregor, J Brandes, A Eikermann. Submitted for publication in Headache.

“Preference comparison of Rizatriptan ODT 10 mg or Sumatriptan Tablet 50 mg in Migraine”.  E Loder, MD, Jan Lewis Brandes, MD, Stephen Silberstein et al 2000.  Submitted for publication.

“Determinants of Patient Preference for Either Rizatriptan Orally Disintegrating Tablet (ODT) 10 mg or Sumatriptan Tablet 50 mg for the Acute Treatment of Migraine”.  J. Brandes, MD, E. Loder, MD, D. Boyle, MD, L. Wang, MD, N. Bohidar, MD, A. Kolodny, MD, N. Santanello, MD, L. Johnson-Pratt, MD. Abstract.  American Academy of Neurology. Philadelphia, PA, May, 2001. 

“Neuromodulation of Late Life Migrainous Accompaniments with Topiramate Therapy”. Susan Roberson, CFNP, Rita Hatfield, LPN, Bryce Dixon, MD, Jan Brandes, MD. Abstract. American Academy of Neurology, Philadelphia, PA. May, 2001. 

“Neuromodulation of Late Life Migrainous Accompaniments with Topiramate Therapy”.  Susan Roberson, CFNP, Rita Hatfield, LPN, Bryce Dixon, MD, Jan Brandes, MD. Abstract. 10th International Headache Congress, New York City, NY.  June 29 – July 2, 2001. 

“Chronic Tension Type Headaches in Medical Clinics of North America”, Brandes JL, Welch KMA.,Ninan Mathew. W.B. Saunders Co. Philadelphia. 2001.  In press.

Jan Lewis Brandes.  Managing Menstrual Migraine.  Headache Quarterly, 2000; Vol XI      (Supp 1): 25-28.

J. Brandes, A. Eikermann, A. MacGregor.  The MAZE (Migraine and Zomig Evaluation) Study.  Presented at EFNS.  Copenhagen, Denmark.  October 17, 2000.

C. Gary Jackson, B. M. McGrew, John Forest, Michael E. Glasscock, Matthew Hanson, Carl R. Hampf, John T. Ramsey, and Jan L. Brandes.  Comparison of Postoperative Headache after Retrosigmoid Approach:  Vestibular Nerve Section vs. Vestibular

Schwannoma Resection. American Journal Otology.  2000.

Jan Lewis Brandes and Elizabeth Loder.  Migraine A Predictor for the Presence of Other Serotonergic Disorders.  Abstract.  Headache World 2000, London England.  September 2000.

J. Brandes, A. Eikermann, A. MacGregor.  MAZE (Migraine and Zomig Evaluation) Survey.  Presented at Headache World 2000, London, England.  September 2000.

Jan Lewis Brandes.  Migraine Induced by Interferon Beta Therapy for Multiple Sclerosis.  42nd Annual Scientific Meeting of the American Headache Society.  Poster Presentation, Montreal, Canada.  June 23, 2000.

Jan Lewis Brandes. Managing Menstrual Migraine. Published in Headache Q 2000; Supplement 1:25-28.

Jan Lewis Brandes.  Migraine Induced by Interferon Beta Therapy for Multiple Sclerosis.  Presented at the 2000 American Academy of Neurology Scientific Program.  52nd Annual Meeting of the American Academy of Neurology.  San Diego, California.  May 4, 2000.

Jan Lewis Brandes.  Vertical Stimulation Triggers Migraine with Aura in Post-Infarction Primary Visual Cortex.  Accepted for the 41st Annual Scientific Meeting of the American Association for the Study of Headache.  Poster Presentation, Boston, Massachusetts.  June 12, 1998.

Jan Lewis Brandes, Matthew Hanson, C. Gary Jackson, Michael E. Glasscock III, 1998.  The Post Craniotomy Headache Syndrome.  Accepted for the 41st Annual Scientific

Meeting of the American Association for the Study of Headache.  Poster Presentation, Boston, Massachusetts.  June 12, 1999.

Jan Lewis Brandes. Vertical Stimulation Triggers Migraine with Aura in Post-Infarction Primary Visual Cortex. Presented at the 1999 American Academy of Neurology

Scientific Program. American Academy of Neurology National Meeting, Toronto, Ontario, Canada.  April 29, 1999.

Jan Lewis Brandes, Matthew Hanson, C. Gary Jackson, Michael E. Glasscock III, 1998. The Post Craniotomy Headache Syndrome. 1998 American Academy of Neurology

Scientific Program. Poster Presentation, American Academy of Neurology National Meeting, Minneapolis, Minnesota. April 29, 1998.

Matthew B. Hanson, Michael E. Glasscock III, Jan Lewis Brandes, C. Gary Jackson, 1998.  Medical Treatment of Headache After Suboccipital Acoustic Tumor Removal.  The Laryngoscope, 108; 111-114, August, 1998.

Matthew B. Hanson, Jan Lewis Brandes, C. Gary Jackson, Michael E. Glasscock III.  1998 Medical Treatment of Headache Following Suboccipital Acoustic Tumor Removal.  Presented at the 1998 Eastern Section Meeting of the Triologic Society, The Plaza Hotel, New York, New York. January 30-31, 1998.

Jan Lewis Brandes, M.D. 1998.  Perspectives on Managed Care – Managing with Managed Care.  HEADACHE – Newsletter of the American Council for Headache Education, Volume 9, Issue 1.  Spring 1998.

Jan Lewis Brandes M.D. 1998.  Migraine, It’s All in Your Head.  Washington Woman.  35-36.  April/May 1998.

Jan Lewis Brandes, M.D. 1994.  Book Review, Management of Headache and Headache Medications by Lawrence D. Robbins, M.D. (Springer Verlag, New York 1994) Neuro Practice, November 1994.

Kenneth W. Sharp, M.D. and Jan Lewis Brandes, M.D. 1990.  Local Resection of Tumors of the Ampulla of Vater.  The American Surgeon 56:  214-217.

J. Lewis, George Pauli, and Hanns Ludwig.  1986.  A comparison of Common Antigenic Determinants for the gA/gB Glycoprotein in BHV and HSV-1,2 Using Monoclonal Antibodies.  Presented at the European Conference on Herpes-viruses.  Mainz, Germany.

J. Lewis Brandes, Edward Smith, and J. H. Park.  1985.  Effects of Vitamin E on the ability of Penicillamine to Protect Against Allozan-Induced Diabetes.  Vanderbilt University Summer Research on Diabetes Symposium, Nashville, Tennessee.  Presented August 1985.

J. Lewis, L Kucera, R. Eberle, and R. Courtney.  1982.  Detection of Herpes Simplex Virus Type 2 Glycoproteins Expressed in Virus-Transformed Cells.  J. of Virology. 42(1):  275-282.

J. Lewis, L.Kucera, R. Eberle, and R. Courtney.  1980.  Identification of Specific Herpes Simplex Virus Type 2 (HSV-2) Glycoproteins Expressed in HSV-2 Transformed Cells.  Presented at the fifth Cole Spring Harbor meeting on Herpes – Viruses.